Trials / Completed
CompletedNCT01776528
Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants
A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety and tolerability of NGM282, both single dose and multiple doses, in normal healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM282 | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2013-01-28
- Last updated
- 2013-12-31
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01776528. Inclusion in this directory is not an endorsement.